361 related articles for article (PubMed ID: 16211558)
1. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
Allard D; Amsellem S; Abifadel M; Trillard M; Devillers M; Luc G; Krempf M; Reznik Y; Girardet JP; Fredenrich A; Junien C; Varret M; Boileau C; Benlian P; Rabès JP
Hum Mutat; 2005 Nov; 26(5):497. PubMed ID: 16211558
[TBL] [Abstract][Full Text] [Related]
2. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
[TBL] [Abstract][Full Text] [Related]
4. LDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a Taiwanese population.
Yang KC; Su YN; Shew JY; Yang KY; Tseng WK; Wu CC; Lee YT
J Formos Med Assoc; 2007 Oct; 106(10):799-807. PubMed ID: 17964958
[TBL] [Abstract][Full Text] [Related]
5. Mutational heterogeneity in low-density lipoprotein receptor gene related to familial hypercholesterolemia in Morocco.
Chater R; Aït Chihab K; Rabès JP; Varret M; Chabraoui L; El Jahiri Y; Adlouni A; Boileau C; Kettani A; El Messal M
Clin Chim Acta; 2006 Nov; 373(1-2):62-9. PubMed ID: 16806138
[TBL] [Abstract][Full Text] [Related]
6. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Abifadel M; Varret M; Rabès JP; Allard D; Ouguerram K; Devillers M; Cruaud C; Benjannet S; Wickham L; Erlich D; Derré A; Villéger L; Farnier M; Beucler I; Bruckert E; Chambaz J; Chanu B; Lecerf JM; Luc G; Moulin P; Weissenbach J; Prat A; Krempf M; Junien C; Seidah NG; Boileau C
Nat Genet; 2003 Jun; 34(2):154-6. PubMed ID: 12730697
[TBL] [Abstract][Full Text] [Related]
7. Effect of a splice site mutation in LDLR gene and two variations in PCSK9 gene in Tunisian families with familial hypercholesterolaemia.
Jelassi A; Slimani A; Jguirim I; Najah M; Maatouk F; Varret M; Slimane MN
Ann Clin Biochem; 2011 Jan; 48(Pt 1):83-6. PubMed ID: 21115573
[TBL] [Abstract][Full Text] [Related]
8. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
[TBL] [Abstract][Full Text] [Related]
9. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
Abifadel M; Rabès JP; Jambart S; Halaby G; Gannagé-Yared MH; Sarkis A; Beaino G; Varret M; Salem N; Corbani S; Aydénian H; Junien C; Munnich A; Boileau C
Hum Mutat; 2009 Jul; 30(7):E682-91. PubMed ID: 19319977
[TBL] [Abstract][Full Text] [Related]
10. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Inoue T; Mori M; Tada H; Nakanishi C; Yagi K; Yamagishi M; Ueda K; Takegoshi T; Miyamoto S; Inazu A; Koizumi J;
Atherosclerosis; 2014 Sep; 236(1):54-61. PubMed ID: 25014035
[TBL] [Abstract][Full Text] [Related]
11. APOE p.Leu167del mutation in familial hypercholesterolemia.
Awan Z; Choi HY; Stitziel N; Ruel I; Bamimore MA; Husa R; Gagnon MH; Wang RH; Peloso GM; Hegele RA; Seidah NG; Kathiresan S; Genest J
Atherosclerosis; 2013 Dec; 231(2):218-22. PubMed ID: 24267230
[TBL] [Abstract][Full Text] [Related]
12. Molecular spectrum of autosomal dominant hypercholesterolemia in France.
Marduel M; Carrié A; Sassolas A; Devillers M; Carreau V; Di Filippo M; Erlich D; Abifadel M; Marques-Pinheiro A; Munnich A; Junien C; ; Boileau C; Varret M; Rabès JP
Hum Mutat; 2010 Nov; 31(11):E1811-24. PubMed ID: 20809525
[TBL] [Abstract][Full Text] [Related]
13. Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: importance of genetic testing in the entire family.
Garcia-Garcia AB; Ivorra C; Martinez-Hervas S; Blesa S; Fuentes MJ; Puig O; Martín-de-Llano JJ; Carmena R; Real JT; Chaves FJ
Atherosclerosis; 2011 Oct; 218(2):423-30. PubMed ID: 21868016
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
Ouguerram K; Chetiveaux M; Zair Y; Costet P; Abifadel M; Varret M; Boileau C; Magot T; Krempf M
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1448-53. PubMed ID: 15166014
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels.
Huijgen R; Sjouke B; Vis K; de Randamie JS; Defesche JC; Kastelein JJ; Hovingh GK; Fouchier SW
Hum Mutat; 2012 Feb; 33(2):448-55. PubMed ID: 22095935
[TBL] [Abstract][Full Text] [Related]
16. The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.
Drouin-Chartier JP; Tremblay AJ; Hogue JC; Ooi TC; Lamarche B; Couture P
Metabolism; 2015 Nov; 64(11):1541-7. PubMed ID: 26371983
[TBL] [Abstract][Full Text] [Related]
17. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene.
Tada H; Kawashiri MA; Ohtani R; Noguchi T; Nakanishi C; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
Atherosclerosis; 2011 Dec; 219(2):663-6. PubMed ID: 21872251
[TBL] [Abstract][Full Text] [Related]
18. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
[TBL] [Abstract][Full Text] [Related]
19. No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes.
Damgaard D; Jensen JM; Larsen ML; Soerensen VR; Jensen HK; Gregersen N; Jensen LG; Faergeman O
Atherosclerosis; 2004 Dec; 177(2):415-22. PubMed ID: 15530918
[TBL] [Abstract][Full Text] [Related]
20. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
Abifadel M; Rabès JP; Devillers M; Munnich A; Erlich D; Junien C; Varret M; Boileau C
Hum Mutat; 2009 Apr; 30(4):520-9. PubMed ID: 19191301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
